TB-500 Sleep Impact and Optimization: What the Evidence Shows
HealthRX.com
No human evidence shows TB-500 changes sleep
At a glance
- Compound / Synthetic 7-amino-acid fragment (residues 17 to 23) of thymosin beta-4 [1]
- Regulatory status / Not FDA-approved and not on FDA's compounding bulk substances list [1][2]
- Human sleep data / None found [1]
- Human pharmacokinetics / None found by any route [1]
- Approved dose / None [1]
- Sport status / WADA S2.3, prohibited at all times [3]
What TB-500 is
TB-500 is a synthetic 7-amino-acid fragment of thymosin beta-4 (residues 17 to 23), N-acetylated, with a molecular weight of about 889 g/mol; it is not the full 43-amino-acid protein [1]. Human trials exist for full-length thymosin beta-4, not TB-500. In one phase 1 trial of recombinant human thymosin beta-4, 54 healthy volunteers were enrolled in single-dose intravenous cohorts (0.05 to 25 microgram/kg) and 30 in multiple-dose cohorts (daily for 10 days). Participants received either the drug or placebo, and adverse events were mild to moderate with none serious [4]. Those studies tested a different molecule and do not show what TB-500 does [1].
What the data say, and don't say, about sleep
FDA found no human pharmacodynamic data for TB-500 [1] and no in-vivo animal study of TB-500 for wound healing [1]. In an in-vitro scratch-wound test, TB-500 at 50 microgram/mL did not induce wound closure in fibroblast cultures [1]. None of this addresses sleep.
Questions worth asking
Dose and injection timing
There is no approved dose and no human dosing study of TB-500 [1]; the nomination FDA reviewed proposed a 3 mg/mL lyophilized powder for subcutaneous or intramuscular injection [1]. With no human pharmacokinetic data, there is no measured half-life in people and no measured time course to schedule an injection around [1]. Animal data show subcutaneous or intraperitoneal dosing reaches the bloodstream and is broken into smaller peptides; no intramuscular animal studies were found [1].
Safety
FDA's adverse-event database search through March 26, 2025 retrieved no TB-500 reports, and FDA found no published case reports, so safety in humans is unknown [1]. FDA's stated concern for injectable TB-500 is immunogenicity, potentially amplified by aggregation and impurities; it found no immunogenicity, aggregation or nonclinical toxicity studies [1].
FDA's BPC-157 review describes one woman who developed widespread skin hyperpigmentation and gum darkening within a week of using a 5 mg/5 mg BPC-157 plus TB-500 product subcutaneously twice daily, recurring on re-trial; because the product held two peptides, FDA could not tell which caused it [5]. TB-500 is not FDA-approved, so there is no FDA-approved TB-500 label with dosing or interaction information [1].
Regulatory status
TB-500 is not FDA-approved [1]. FDA found no USP or National Formulary monograph, no approved drug containing it, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, and none authorized by the European Medicines Agency [1]. FDA staff recommended against adding it to the compounding bulk substances list [1]. The Pharmacy Compounding Advisory Committee voted in favor on July 23, 2026, but its advice is non-binding and TB-500 is not on the list [6]. HHS's October 2026 enforcement-discretion policy naming TB-500 is a draft, non-binding, and not an approval [7][8]. WADA prohibits thymosin beta-4 and derivatives including TB-500 at all times [3].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Does TB-500 improve sleep?
Is there a best time of day to inject TB-500 for sleep?
Does TB-500 cause drowsiness or insomnia?
Can you take melatonin or magnesium with TB-500?
References
Show all 8 referencesHide references
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- World Anti-Doping Agency.
- Wang X, Liu L, Qi L, Lei C, Li P, Wang Y, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.